Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Diagnosis of latent tuberculosis infection (tuberculosis screening) in HIV-infected patients

Dick Menzies, MD, MSc
Section Editor
C Fordham von Reyn, MD
Deputy Editor
Elinor L Baron, MD, DTMH


Approximately one-third of the world's population is estimated to be latently infected with Mycobacterium tuberculosis, representing a major reservoir of potential active disease [1]. The intersection of the human immunodeficiency virus (HIV) and tuberculosis (TB) epidemics has led to a major upsurge in TB cases, particularly in resource-limited settings where TB is prevalent [2-4]. However, the risk of active TB disease in HIV-infected patients can be reduced with preventive therapy, thus emphasizing the importance of appropriate diagnostic and therapeutic interventions for latent tuberculosis infection (LTBI) [5-7].

This topic will address the diagnosis of LTBI in the HIV-infected patient. Treatment of LTBI in the HIV-infected host is discussed in detail elsewhere. (See "Treatment of latent tuberculosis infection in HIV-infected adults".)

Diagnostic testing for LTBI in the HIV-uninfected host is discussed elsewhere.


What is latent tuberculosis? — Tuberculosis (TB) infection is caused by inhalation of viable bacilli, which usually persist in an inactive state, known as latent TB infection (LTBI), or sometimes progress rapidly to active TB disease. Persons with LTBI are asymptomatic and not infectious. However, these latent TB bacilli remain viable and may "reactivate" years later and cause active symptomatic, and often transmissible, TB disease [8].

HIV as a risk factor for active tuberculosis — Concomitant infection with human immunodeficiency virus (HIV) is a leading risk factor for progression from LTBI to active disease [9,10]. In nonendemic areas, the rate of progression to active TB disease is 5 to 8 percent/year among HIV-infected patients with LTBI, compared with a 10 percent lifetime risk in the general population [11]. In resource-limited settings, where TB is the leading cause of death, the risk of reactivation is in the range of 10 percent per year [12,13]. Hence, prevention of active TB disease is a high priority in HIV care [6]. (See "Treatment of latent tuberculosis infection in HIV-infected adults", section on 'Risk factors for progression'.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Jan 05, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017; 64:e1.
  2. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011; 2011.
  3. World Health Organization. Guidelines for Intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings, Geneva, 2011.
  4. World Health Organization. Global Tuberculosis Report 2009. http://www.who.int/tb/publications/global_report/2009/en/index.html (Accessed on August 25, 2011).
  5. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; :CD000171.
  6. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on July 10, 2017).
  7. World Health Organization. WHO Three 'I's meeting: intensified case finding, isoniazid preventive therapy and TB infection control for people living with HIV. http://www.who.int/hiv/pub/tb/3is_mreport/en/index.html (Accessed on September 20, 2011).
  8. CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15).
  9. van der Sande MA, Schim van der Loeff MF, Bennett RC, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004; 18:1933.
  10. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060.
  11. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.
  12. World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing: 2010. World Health Organization, Geneva 2011 (WHO/HTM/TB/2010.362).
  13. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic--when will we act? Lancet 2010; 375:1906.
  14. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191:150.
  15. Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008; 198:1590.
  16. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.
  17. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75.
  18. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464.
  19. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.
  20. Tuberculosis Prevention and Control, Public Health Agency of Canada, the Canadian Lung Association. Canadian Lung Association, 6th ed, Long RL, Ellis E (Eds), Public Health Agency of Canada, Toronto 2007.
  21. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44:94.
  22. Fisk TL, Hon HM, Lennox JL, et al. Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS 2003; 17:1102.
  23. Aisu T, Raviglione MC, van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 1995; 9:267.
  24. Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293:2719.
  25. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175:737.
  26. Zhang M, Gong J, Iyer DV, et al. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994; 94:2435.
  27. Sutherland R, Yang H, Scriba TJ, et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006; 20:821.
  28. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10:1192.
  29. Menzies D, Doherty TM. Diagnosis of latent tuberculosis infection. In: Reichman and Hershfield's Tuberculosis, a comprehensive international approach, Raviglione MC (Ed), Informa Healthcare USA, New York 2006. p.215.
  30. Worodria W, Massinga-Loembe M, Mazakpwe D, et al. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr 2011; 58:32.
  31. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997; 337:315.
  32. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801.
  33. Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with HIV infection. The pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1996; 153:1982.
  34. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46:1.
  35. Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 2000; 4:895.
  36. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:1588.
  37. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274:143.
  38. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56:230.
  39. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177.
  40. Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006; 7:56.
  41. Adams LV, Waddell RD, Von Reyn CF. T-SPOT.TB Test(R) results in adults with Mycobacterium avium complex pulmonary disease. Scand J Infect Dis 2008; 40:196.
  42. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146:340.
  43. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48:954.
  44. Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007; 150:238.
  45. Elliott JH, Vohith K, Saramony S, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009; 200:1736.
  46. World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO, Geneva 2015.
  47. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175:514.
  48. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:45.
  49. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17:806.
  50. Hoppe LE, Kettle R, Eisenhut M, et al. Tuberculosis--diagnosis, management, prevention, and control: summary of updated NICE guidance. BMJ 2016; 352:h6747.
  51. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59:1.
  52. Canadian Tuberculosis Committee. Recommendations on Interferon Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection—2010 Update. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10pdf/36-acs-5.pdf (Accessed on October 10, 2011).
  53. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40:1500.
  54. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8:e1000391.
  55. WHO. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, WHO, 2011.
  56. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067.
  57. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011; 8:e1001061.
  58. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11:819.
  59. Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012; 54:1071.
  60. Gupta A, Chandrasekhar A, Gupte N, et al. Symptom screening among HIV-infected pregnant women is acceptable and has high negative predictive value for active tuberculosis. Clin Infect Dis 2011; 53:1015.
  61. Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10:523.
  62. Rangaka MX, Wilkinson RJ, Glynn JR, et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. Clin Infect Dis 2012; 55:1698.